Der Melaningehalt der Iris kann sich auf die Augengesundheit auswirken. Denn so wie in der Haut schützt das Melanin auch in der Iris vor dem Einfluss des Sonnenlichts. Es filtert sowohl den sichtbaren Teil des Lichtspektrums – Menschen mit sehr hellen Augen reagieren daher besonders empfindlich auf starken Lichteinfall – als auch dessen UV-Anteil. Bei niedrigerem Melaningehalt steigt deshalb auch das Risiko, an einem uvealen Melanom zu erkranken. «Dieser Krebstyp ist zwar sehr selten, er findet sich jedoch bei Menschen europäischer Abstammung 20bis 30-mal häufiger als bei Menschen asiatischer oder afrikanischer Abstammung», erläutert Prof. Nikolaos Bechrakis (Essen). Mit einem geringeren Schutz vor den schädlichen Auswirkungen des Sonnenlichts lässt sich vermutlich auch die Beobachtung erklären, dass Menschen mit hellen Augen eher eine AMD entwickeln. «Eine umfangreiche Metaanalyse mit fast 130 000 Teilnehmenden konnte belegen, dass zumindest die Kompass Ophthalmol 2023;9:128–131 DOI: 10.1159/000533823
{"title":"Spektrum Ophthalmologie – wissenswert, kompakt, anregend","authors":"","doi":"10.1159/000533823","DOIUrl":"https://doi.org/10.1159/000533823","url":null,"abstract":"Der Melaningehalt der Iris kann sich auf die Augengesundheit auswirken. Denn so wie in der Haut schützt das Melanin auch in der Iris vor dem Einfluss des Sonnenlichts. Es filtert sowohl den sichtbaren Teil des Lichtspektrums – Menschen mit sehr hellen Augen reagieren daher besonders empfindlich auf starken Lichteinfall – als auch dessen UV-Anteil. Bei niedrigerem Melaningehalt steigt deshalb auch das Risiko, an einem uvealen Melanom zu erkranken. «Dieser Krebstyp ist zwar sehr selten, er findet sich jedoch bei Menschen europäischer Abstammung 20bis 30-mal häufiger als bei Menschen asiatischer oder afrikanischer Abstammung», erläutert Prof. Nikolaos Bechrakis (Essen). Mit einem geringeren Schutz vor den schädlichen Auswirkungen des Sonnenlichts lässt sich vermutlich auch die Beobachtung erklären, dass Menschen mit hellen Augen eher eine AMD entwickeln. «Eine umfangreiche Metaanalyse mit fast 130 000 Teilnehmenden konnte belegen, dass zumindest die Kompass Ophthalmol 2023;9:128–131 DOI: 10.1159/000533823","PeriodicalId":477056,"journal":{"name":"Karger Kompass","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135312316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Stuart Elborn, Francesco Blasi, Pierre-Régis Burgel, Daniel Peckham
Las infecciones bacterianas recurrentes y crónicas son frecuentes en pacientes con fibrosis quística (FQ), y contribuyen al deterioro de la función pulmonar. Los antibióticos constituyen la base del tratamiento de las exacerbaciones e infecciones bacterianas crónicas en la FQ. Los antibióticos inhalados son eficaces para tratar infecciones bacterianas respiratorias crónicas y erradicar a Pseudomonas aeruginosa de las vías respiratorias, con efectos adversos sistémicos limitados. En la última década, los moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) de alta eficacia se han convertido en una nueva opción terapéutica que corrige/reabre parcialmente el transporte de cloruro en pacientes con mutaciones específicas del CFTR, restaurando la hidratación del moco y mejorando el aclaramiento mucociliar. La reciente combinación triple de moduladores CFTR está aprobada para ∼80–90% de la población con FQ, y reduce significativamente las exacerbaciones pulmonares y mejora los síntomas respiratorios y la función pulmonar. Los moduladores de CFTR han puesto en el centro de atención del tratamiento sintomático a la medicina personalizada/de precisión, al dirigirse a defectos de CFTR específicos del genotipo. Aunque son muy eficaces, no normalizan por completo la fisiología pulmonar, no detienen la inflamación ni resuelven el daño pulmonar crónico, como las bronquiectasias. Es probable que el impacto de estos nuevos fármacos en la salud pulmonar cambie el tratamiento futuro de las infecciones pulmonares crónicas en pacientes con FQ. Este artículo revisa el papel de los antibióticos inhalados en la era de los moduladores de CFTR.
{"title":"El papel de los antibióticos inhalados en la era de los moduladores de CFTR de alta eficacia","authors":"J. Stuart Elborn, Francesco Blasi, Pierre-Régis Burgel, Daniel Peckham","doi":"10.1159/000533457","DOIUrl":"https://doi.org/10.1159/000533457","url":null,"abstract":"Las infecciones bacterianas recurrentes y crónicas son frecuentes en pacientes con fibrosis quística (FQ), y contribuyen al deterioro de la función pulmonar. Los antibióticos constituyen la base del tratamiento de las exacerbaciones e infecciones bacterianas crónicas en la FQ. Los antibióticos inhalados son eficaces para tratar infecciones bacterianas respiratorias crónicas y erradicar a <i>Pseudomonas aeruginosa</i> de las vías respiratorias, con efectos adversos sistémicos limitados. En la última década, los moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) de alta eficacia se han convertido en una nueva opción terapéutica que corrige/reabre parcialmente el transporte de cloruro en pacientes con mutaciones específicas del CFTR, restaurando la hidratación del moco y mejorando el aclaramiento mucociliar. La reciente combinación triple de moduladores CFTR está aprobada para ∼80–90% de la población con FQ, y reduce significativamente las exacerbaciones pulmonares y mejora los síntomas respiratorios y la función pulmonar. Los moduladores de CFTR han puesto en el centro de atención del tratamiento sintomático a la medicina personalizada/de precisión, al dirigirse a defectos de CFTR específicos del genotipo. Aunque son muy eficaces, no normalizan por completo la fisiología pulmonar, no detienen la inflamación ni resuelven el daño pulmonar crónico, como las bronquiectasias. Es probable que el impacto de estos nuevos fármacos en la salud pulmonar cambie el tratamiento futuro de las infecciones pulmonares crónicas en pacientes con FQ. Este artículo revisa el papel de los antibióticos inhalados en la era de los moduladores de CFTR.","PeriodicalId":477056,"journal":{"name":"Karger Kompass","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136257266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Recently, cystic fibrosis transmembrane regulator modulator therapy with elexacaftor/tezacaftor/ivacaftor has become available for children with cystic fibrosis (CF) carrying at least one F508del mutation. Objective: To assess the intermediate term effects of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis in a real-world setting. Methods: We performed a retrospective analysis of records of children with cystic fibrosis, who started elexacaftor/tezacaftor/ivacaftor between 8/2020 and 10/2022. Pulmonary function tests, nutritional status, sweat chloride and laboratory data were assessed before, 3 and 6 months after the start of elexacaftor/tezacaftor/ivacaftor respectively. Results: Elexacaftor/tezacaftor/ivacaftor was started in 22 children 6–11 years and in 24 children 12–17 years. Twenty-seven (59%) patients were homozygous for F508del (F/F) and 23 (50%) patients were transitioned from ivacaftor/lumacaftor (IVA/LUM) or tezacaftor/ivacaftor (TEZ/IVA) to elexacaftor/tezacaftor/ivacaftor. Overall, mean sweat chloride concentration decreased by 59.3 mmol/L (95% confidence interval: -65.0 to -53.7 mmol/L, p < 0.0001) under elexacaftor/tezacaftor/ivacaftor. Sweat chloride concentration also decreased significantly after transition from IVA/LUM or TEZ/IVA to elexacaftor/tezacaftor/ivacaftor (-47.8 mmol/l; 95% confidence interval: -57.6 to -37.8 mmol/l, n = 14, p < 0.0001). Sweat chloride reduction was more marked in children with the F/F than in those with the F/MF genotype (69.4 vs 45.9 mmol/L, p < 0.0001). At 3 months follow-up, body-mass-index-z-score increased by 0.31 (95% CI, 0.2–0.42, p < 0.0001) with no further increase at 6 months. BMI-for-age-z-score was more markedly improved in the older group. Overall pulmonary function (percent predicted FEV1) at 3 months follow-up increased by 11.4% (95% CI: 8.0–14.9, p < 0.0001) with no further significant change after 6 months. No significant differences were noted between the age groups. Children with the F/MF genotype had a greater benefit regarding nutritional status and pulmonary function tests than those with the F/F genotype. Adverse events led to elexacaftor/tezacaftor/ivacaftor dose reduction in three cases and a temporary interruption of therapy in four cases. Conclusion: In a real-world setting, elexacaftor/tezacaftor/ivacaftor therapy had beneficial clinical effects and a good safety profile in eligible children with cystic fibrosis comparable to previously published data from controlled clinical trials. The positive impact on pulmonary function tests and nutritional status seen after 3 months of elexacaftor/tezacaftor/ivacaftor therapy was sustained at 6 months follow-up.
{"title":"Niños con fibrosis quística: Impacto en la vida real de la terapia moduladora de CFTR altamente efectiva","authors":"Maria René Álvarez-Arroyo","doi":"10.1159/000533336","DOIUrl":"https://doi.org/10.1159/000533336","url":null,"abstract":"<b>Introduction:</b> Recently, cystic fibrosis transmembrane regulator modulator therapy with elexacaftor/tezacaftor/ivacaftor has become available for children with cystic fibrosis (CF) carrying at least one <i>F508del</i> mutation. <b>Objective:</b> To assess the intermediate term effects of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis in a real-world setting. <b>Methods:</b> We performed a retrospective analysis of records of children with cystic fibrosis, who started elexacaftor/tezacaftor/ivacaftor between 8/2020 and 10/2022. Pulmonary function tests, nutritional status, sweat chloride and laboratory data were assessed before, 3 and 6 months after the start of elexacaftor/tezacaftor/ivacaftor respectively. <b>Results:</b> Elexacaftor/tezacaftor/ivacaftor was started in 22 children 6–11 years and in 24 children 12–17 years. Twenty-seven (59%) patients were homozygous for <i>F508del</i> (F/F) and 23 (50%) patients were transitioned from ivacaftor/lumacaftor (IVA/LUM) or tezacaftor/ivacaftor (TEZ/IVA) to elexacaftor/tezacaftor/ivacaftor. Overall, mean sweat chloride concentration decreased by 59.3 mmol/L (95% confidence interval: -65.0 to -53.7 mmol/L, <i>p</i> &#x3c; 0.0001) under elexacaftor/tezacaftor/ivacaftor. Sweat chloride concentration also decreased significantly after transition from IVA/LUM or TEZ/IVA to elexacaftor/tezacaftor/ivacaftor (-47.8 mmol/l; 95% confidence interval: -57.6 to -37.8 mmol/l, n = 14, <i>p</i> &#x3c; 0.0001). Sweat chloride reduction was more marked in children with the F/F than in those with the F/MF genotype (69.4 vs 45.9 mmol/L, p &#x3c; 0.0001). At 3 months follow-up, body-mass-index-z-score increased by 0.31 (95% CI, 0.2–0.42, <i>p</i> &#x3c; 0.0001) with no further increase at 6 months. BMI-for-age-z-score was more markedly improved in the older group. Overall pulmonary function (percent predicted FEV<sub>1</sub>) at 3 months follow-up increased by 11.4% (95% CI: 8.0–14.9, <i>p</i> &#x3c; 0.0001) with no further significant change after 6 months. No significant differences were noted between the age groups. Children with the F/MF genotype had a greater benefit regarding nutritional status and pulmonary function tests than those with the F/F genotype. Adverse events led to elexacaftor/tezacaftor/ivacaftor dose reduction in three cases and a temporary interruption of therapy in four cases. <b>Conclusion:</b> In a real-world setting, elexacaftor/tezacaftor/ivacaftor therapy had beneficial clinical effects and a good safety profile in eligible children with cystic fibrosis comparable to previously published data from controlled clinical trials. The positive impact on pulmonary function tests and nutritional status seen after 3 months of elexacaftor/tezacaftor/ivacaftor therapy was sustained at 6 months follow-up.","PeriodicalId":477056,"journal":{"name":"Karger Kompass","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136257267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dupilumab: Zulassung als erste Systemtherapie bei PN","authors":"","doi":"10.1159/000534684","DOIUrl":"https://doi.org/10.1159/000534684","url":null,"abstract":"","PeriodicalId":477056,"journal":{"name":"Karger Kompass","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135561432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Image-guided percutaneous thermal ablation is an established treatment option for early-stage lung cancer in medically inoperable patients but carries a high risk of pleura-related complications, particularly pneumothorax. Objective: This study aimed to determine if image-guided transbronchial microwave ablation (tMWA) is a feasible approach to treat peripheral stage 1 lung cancer. Method: A prospective, single-arm, multicenter study sought to enroll 40 adults who were medically inoperable or declined surgery for peripheral stage 1 lung tumors (≤20 mm). Ablation was performed using navigational bronchoscopy and a flexible MWA probe, guided by cone-beam CT with augmented fluoroscopy. Follow-up at 1, 6, and 12 months included CT imaging of the ablation zone and possible tumor recurrence, adverse events (AEs), pulmonary function, and quality of life. Results: Across 2 sites, 11 tumors (10 NSCLC, 1 carcinoid) were treated in 10 enrolled patients. Median tumor diameter was 13 × 14 mm (7–19 mm) and median minimum ablative margin was 11 mm (5–19 mm). Technical success and technique efficacy were achieved in all patients. No tumor recurrence was seen during 12-month follow-up. No pneumothorax, pleural effusion, or bronchopleural fistula were noted. Minor AEs included scant hemoptysis, pain, cough, and dyspnea. Two serious AEs occurred ≤30 days of ablation and included a COPD exacerbation (day 9) and a death of unknown cause (day 15). The death led the sponsor to halt enrollment. Pulmonary function and quality-of-life indices remained stable.
背景:图像引导下经皮热消融术是早期肺癌医学上不能手术的患者的一种成熟的治疗选择，但它具有胸膜相关并发症的高风险，特别是气胸。目的:本研究旨在确定图像引导下经支气管微波消融(tMWA)是否是治疗周围期1期肺癌的可行方法。方法:一项前瞻性、单臂、多中心研究，旨在招募40名因周围期1期肺肿瘤(≤20 mm)无法手术或拒绝手术的成年人。使用导航支气管镜和柔性MWA探针进行消融，锥形束CT引导增强透视。随访1、6和12个月，包括消融区CT成像、肿瘤复发可能性、不良事件(ae)、肺功能和生活质量。结果:在10名入组患者中，在2个部位治疗了11个肿瘤(10个非小细胞肺癌，1个类癌)。中位肿瘤直径为13 × 14 mm (7 ~ 19 mm)，中位最小消融缘为11 mm (5 ~ 19 mm)。所有患者均获得技术成功和技术效果。随访12个月未见肿瘤复发。无气胸、胸腔积液、支气管胸膜瘘。轻微的不良反应包括少量咯血、疼痛、咳嗽和呼吸困难。消融≤30天发生2例严重ae，包括COPD加重(第9天)和不明原因死亡(第15天)。死亡导致赞助商停止招收。肺功能和生活质量指标保持稳定。
{"title":"Risikobehaftet? Transbronchiale Mikrowellenablation beim nicht metastasierten Lungenkarzinom","authors":"Lars Hagmeyer","doi":"10.1159/000533174","DOIUrl":"https://doi.org/10.1159/000533174","url":null,"abstract":"Background: Image-guided percutaneous thermal ablation is an established treatment option for early-stage lung cancer in medically inoperable patients but carries a high risk of pleura-related complications, particularly pneumothorax. Objective: This study aimed to determine if image-guided transbronchial microwave ablation (tMWA) is a feasible approach to treat peripheral stage 1 lung cancer. Method: A prospective, single-arm, multicenter study sought to enroll 40 adults who were medically inoperable or declined surgery for peripheral stage 1 lung tumors (≤20 mm). Ablation was performed using navigational bronchoscopy and a flexible MWA probe, guided by cone-beam CT with augmented fluoroscopy. Follow-up at 1, 6, and 12 months included CT imaging of the ablation zone and possible tumor recurrence, adverse events (AEs), pulmonary function, and quality of life. Results: Across 2 sites, 11 tumors (10 NSCLC, 1 carcinoid) were treated in 10 enrolled patients. Median tumor diameter was 13 × 14 mm (7–19 mm) and median minimum ablative margin was 11 mm (5–19 mm). Technical success and technique efficacy were achieved in all patients. No tumor recurrence was seen during 12-month follow-up. No pneumothorax, pleural effusion, or bronchopleural fistula were noted. Minor AEs included scant hemoptysis, pain, cough, and dyspnea. Two serious AEs occurred ≤30 days of ablation and included a COPD exacerbation (day 9) and a death of unknown cause (day 15). The death led the sponsor to halt enrollment. Pulmonary function and quality-of-life indices remained stable.","PeriodicalId":477056,"journal":{"name":"Karger Kompass","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136029374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mukoviszidose: Wegbereiter für die Diagnostik und Therapie anderer seltener Lungenerkrankungen","authors":"Ernst Rietschel","doi":"10.1159/000533723","DOIUrl":"https://doi.org/10.1159/000533723","url":null,"abstract":"","PeriodicalId":477056,"journal":{"name":"Karger Kompass","volume":"83 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The Cystic Fibrosis Foundation Patient Registry (CFFPR) reports a high prevalence of asthma (34.6%) in people with Cystic Fibrosis (PwCF). While our current understanding of this relationship is limited, a type 2 inflammatory (T2) phenotype has often been identified in CF patients. Research question: This study aimed to evaluate the relationship between the eosinophilic CF T2 inflammatory phenotype and CF-related pulmonary outcomes and microbiological data. Study design: and methods: We conducted a retrospective chart review of adult patients with CF (18 and older; n = 93) receiving their care at University of Virginia Medical Center adult program from January, 2013 through December, 2018. Data collected included demographic data, CFTR (CF transmembrane conductance regulator) mutation, CF comorbidities, medications, Absolute Eosinophil Counts (AEC) in cells/µL and Immunoglobulin E (IgE) levels in IU/mL. Results: Of 93 patients screened for study eligibility, 74 were included in the final analysis; 19 patients were excluded due to lack of longitudinal data across the study timeline. Lung function decline correlated with increased AEC (p < 0.001) and IgE (p < 0.001) even when adjusting for covariates: age, gender, presence of Pseudomonas spp., MRSA, other bacterial spp., Aspergillus spp., and other fungi (p < 0.001). Univariate analysis demonstrated that people with CF who experienced more than 2 exacerbations requiring hospitalizations and/or intravenous antibiotics a year were more likely to have high AEC (p = 0.018). Logistic regression showed that as AEC increases, the probability that the measurement was taken during a CF exacerbation increases (p = 0.0039). A linear mixed model showed that each additional annual exacerbation event increased on average the log IgE by 0.04. (p = 0.015). This finding remained stable in a multivariate model (p = 0.0145). When adjusted for atopy, log IgE increases as the number of exacerbation events increases (p = 0.022). There was no association between AEC and IgE and microbiological colonization.
{"title":"Fibrosis quística: Facilitar urgentemente el acceso al diagnóstico temprano también en los países emergentes","authors":"Esperanza Figueroa-Hurtado, Diana Lizbeth Ortiz-Farías, Arturo Cortés-Telles","doi":"10.1159/000533890","DOIUrl":"https://doi.org/10.1159/000533890","url":null,"abstract":"<b>Background:</b> The Cystic Fibrosis Foundation Patient Registry (CFFPR) reports a high prevalence of asthma (34.6%) in people with Cystic Fibrosis (PwCF). While our current understanding of this relationship is limited, a type 2 inflammatory (T2) phenotype has often been identified in CF patients. <b>Research question:</b> This study aimed to evaluate the relationship between the eosinophilic CF T2 inflammatory phenotype and CF-related pulmonary outcomes and microbiological data. <b>Study design:</b> and methods: We conducted a retrospective chart review of adult patients with CF (18 and older; n = 93) receiving their care at University of Virginia Medical Center adult program from January, 2013 through December, 2018. Data collected included demographic data, CFTR (CF transmembrane conductance regulator) mutation, CF comorbidities, medications, Absolute Eosinophil Counts (AEC) in cells/µL and Immunoglobulin E (IgE) levels in IU/mL. <b>Results:</b> Of 93 patients screened for study eligibility, 74 were included in the final analysis; 19 patients were excluded due to lack of longitudinal data across the study timeline. Lung function decline correlated with increased AEC (p &#x3c; 0.001) and IgE (p &#x3c; 0.001) even when adjusting for covariates: age, gender, presence of <i>Pseudomonas spp.</i>, MRSA, other bacterial spp., <i>Aspergillus spp.</i>, and other fungi (p &#x3c; 0.001). Univariate analysis demonstrated that people with CF who experienced more than 2 exacerbations requiring hospitalizations and/or intravenous antibiotics a year were more likely to have high AEC (p = 0.018). Logistic regression showed that as AEC increases, the probability that the measurement was taken during a CF exacerbation increases (p = 0.0039). A linear mixed model showed that each additional annual exacerbation event increased on average the log IgE by 0.04. (p = 0.015). This finding remained stable in a multivariate model (p = 0.0145). When adjusted for atopy, log IgE increases as the number of exacerbation events increases (p = 0.022). There was no association between AEC and IgE and microbiological colonization.","PeriodicalId":477056,"journal":{"name":"Karger Kompass","volume":"82 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136209832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：